Pasquinucci, Lorella, Turnaturi, Rita, Calò, Girolamo, Pappalardo, Francesco, Ferrari, Federica, Russo, Giulia, Arena, Emanuela, Montenegro, Lucia, Chiechio, Santina, Prezzavento, Orazio, and Parenti, Carmela
Abstract The pivotal role of the stereocenter at the N -substituent of the 6,7-benzomorphan scaffold was investigated combining synthetic and pharmacological approaches. 2 R - and 2 S -diastereoisomers of the multitarget MOR/DOR antinociceptive ligand LP2 (1) were synthesized and their pharmacological profile was evaluated in in vitro and vivo assays. From our results, 2 S -LP2 (5) showed an improved pharmacological profile in comparison to LP2 (1) and 2 R -LP2 (4). 2 S -LP2 (5) elicited an antinociceptive effect with a 1.5- and 3-times higher potency than LP2 (1) and R -antipode (4), respectively. In vivo effect of 2 S -LP2 (5) was consistent with the improved MOR/DOR efficacy profile assessed by radioligand binding assay, to evaluate the opioid receptor affinity, and BRET assay, to evaluate the capability to promote receptor/G-protein and receptor/β-arrestin 2 interaction. 2 S -LP2 (5) was able to activate, with different efficacy, G-protein pathway over β-arrestin 2, behaving as biased agonist at MOR and mainly at DOR. Considering the therapeutic potential of both multitarget MOR/DOR agonism and functional selectivity over G-protein, the 2 S -LP2 (5) biased multitarget MOR/DOR agonist could provide a safer treatment opportunity. Graphical abstract Image 1 Highligthts • The stereocenter role at the N -substituent of the 6,7-benzomorphan scaffold was investigated. • 2 R - and 2 S -diastereoisomers of the multitarget opioid ligand LP2 were synthesized. • 2 S -LP2 showed a better pharmacological profile than 2 R -LP2 in in vitro and in vivo assays. • 2 S -LP2 resulted a biased multitarget MOR/DOR agonist. • 2 S -LP2 elicited an antinociceptive potency 1.5- and 3-times higher than LP2 and R -antipode. [ABSTRACT FROM AUTHOR]